Adaptimmune's immunotherapy looks promising in sarcoma; Roche bets on pipeline to endure biosimilar bite;

@FierceBiotech: GSK, Gates Foundation help immuno-oncology player to $56M Series A round. Story | Follow @FierceBiotech

@JohnCFierce: Relentless masochism... NYT story | Follow @JohnCFierce

> Adaptimmune's ($ADAP) T cell therapy charted a 50% response rate in a trial on patients with tough-to-treat synovial sarcomas. More

> Roche ($RHHBY) said its pipeline of innovative drugs has it poised to withstand the coming effect of biosimilar competition for its older products. News

> Genocea Biosciences ($GNCA) has partnered with Memorial Sloan Kettering Cancer Center to identify T cell responses to novel cancer therapies and find new antigen targets. Item

Medical Device News

@FierceMedDev:Dx Digest: Illumina launches $250M share repurchase program; Foundation Medicine stumbles with Q3 earnings miss. Read more | Follow @FierceMedDev

@VarunSaxena2: Investigational drug enables faster absorption of bioresorbable drug-eluting stents. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Biosensors sells out to Chinese private equity firm for $787M. Story | Follow @EmilyWFierce

> Allergan beefs up in aesthetics with implant purchase. Does M&A suitor Pfizer approve? Report

> Boston Scientific files patent infringement suit against Edwards' Sapien 3 TAVR. Story

> FDA adds another artificial kidney to its Expedited Access Pathway program. News

Pharma News

@FiercePharma: U.S. FDA Form 483 has Indian drugmakers 'spooked'. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: If the quarterly Vivus trend keeps up, I'm pretty sure that we're about to find out they have zero remaining sales reps | Follow @CarlyHFierce

> Pfizer greatly expands free-drugs assistance as 'stopgap' for struggling patients. More

> Turing promises to cut Daraprim price by year's end, if only partially. News

> Vivus counts $25M in Q3 sales, $300M in debt. How can it possibly cover a $200M-plus Qsymia trial? Article

CRO News

> Icon eyes Asia growth with a pair of exec appointments. More

> Catalent ekes out revenue growth in the face of currency troubles. News

> PRA narrows its sales guidance on the way to a record year. Story

> Charles River boosts its 2015 outlook after strong sales quarter. Article

> WuXi pads its revenue on the way to a big buyout decision. More

Pharma Manufacturing News

> Turing again vows to cut drug's cost as compounder starts manufacturing a version. Story

> India's Torrent Pharma targets production from new plant at U.S., EU. More

> Pfizer will transfer manufacturing tech for Prevenar 13. News

> Novo starts in on massive production buildup. Article

> Novartis, others face higher manufacturing costs with CAR-T cell treatments. More

Pharma Asia News

> Indian drugmakers on the hunt for money and growth. More

> Australia looks to save cash by cutting scripts for common drugs. News

> Generic drugs cut costs by $254B in U.S. last year. Story

> AbbVie nears launch of Viekira into crowded Japan HCV battle. Article

> Roche gets temporary court injunction on Herceptin biosimilar in India. News

Suggested Articles

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.

Durect's treatment lowered scores that reflect the likelihood a person with alcoholic hepatitis will die within a certain time in all 19 patients.

AstraZeneca is confident data generated across development show the antibody works despite a pivotal study missing its primary endpoint.